全文获取类型
收费全文 | 2315篇 |
免费 | 111篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 25篇 |
妇产科学 | 140篇 |
基础医学 | 227篇 |
口腔科学 | 35篇 |
临床医学 | 185篇 |
内科学 | 586篇 |
皮肤病学 | 31篇 |
神经病学 | 154篇 |
特种医学 | 95篇 |
外科学 | 417篇 |
综合类 | 14篇 |
一般理论 | 1篇 |
预防医学 | 89篇 |
眼科学 | 61篇 |
药学 | 166篇 |
中国医学 | 3篇 |
肿瘤学 | 190篇 |
出版年
2024年 | 1篇 |
2023年 | 29篇 |
2022年 | 59篇 |
2021年 | 73篇 |
2020年 | 46篇 |
2019年 | 71篇 |
2018年 | 76篇 |
2017年 | 44篇 |
2016年 | 64篇 |
2015年 | 70篇 |
2014年 | 107篇 |
2013年 | 133篇 |
2012年 | 197篇 |
2011年 | 181篇 |
2010年 | 110篇 |
2009年 | 93篇 |
2008年 | 186篇 |
2007年 | 154篇 |
2006年 | 165篇 |
2005年 | 157篇 |
2004年 | 109篇 |
2003年 | 100篇 |
2002年 | 76篇 |
2001年 | 25篇 |
2000年 | 35篇 |
1999年 | 16篇 |
1998年 | 12篇 |
1997年 | 6篇 |
1996年 | 6篇 |
1995年 | 2篇 |
1994年 | 13篇 |
1993年 | 3篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有2445条查询结果,搜索用时 15 毫秒
41.
Hyphantis T Kotsis K Voulgari PV Tsifetaki N Creed F Drosos AA 《Arthritis care & research》2011,63(9):1313-1321
Objective
The Patient Health Questionnaire 9 (PHQ‐9) was developed to screen for depressive disorders in community, primary care, and medical settings. We aimed to estimate its diagnostic accuracy, internal consistency, reliability, and convergent validity in diagnosing major depressive disorder (MDD) in Greek patients with rheumatologic disorders.Methods
In a 2‐phase sampling design study, we recruited 475 patients with established rheumatologic disorders. One of 2 of the high scorers (PHQ‐9 score ≥9, n = 85) and 1 of 3 of the low scorers (PHQ‐9 score 0–8, n = 128) were interviewed using the Mini International Neuropsychiatric Interview to confirm MDD. A receiver operator characteristic curve analysis was performed to confirm the optimum threshold value. The scale's dimensional structure was tested with factor analysis, and internal consistency reliability was assessed with Cronbach's alpha. Psychological distress (Symptom Check List‐90‐Revised [SCL‐90‐R]), disability (Health Assessment Questionnaire disability index), and health‐related quality of life (HRQOL; World Health Organization Quality of Life Instrument [WHOQOL‐BREF]) were also assessed to test convergent validity with bivariate correlations.Results
At an optimum threshold of 10, the PHQ‐9 showed a sensitivity of 81.2% and a specificity of 86.8%. The area under the curve was 0.91. The PHQ‐9 presented unidimensional structure with good scale reliability (α = 0.82). The PHQ‐9 score presented the greatest correlations with SCL‐90‐R depression (r = 0.736) and WHOQOL‐BREF mental HRQOL scales (r = ?0.571), and all other correlations with disability and HRQOL were in the expected direction.Conclusion
At a cutoff of 10, the PHQ‐9 is an accurate, reliable, and valid measure for screening for MDD among Greek rheumatologic patients.42.
Nicolas C. Nicolaides Agaristi Lamprokostopoulou Alexandros Polyzos Tomoshige Kino Eleni Katsantoni Panagiota Triantafyllou Athanasios Christophoridis George Katzos Maria Dracopoulou Amalia Sertedaki George P. Chrousos Evangelia Charmandari 《European journal of clinical investigation》2015,45(12):1306-1315
43.
Evripidis Kaltsonoudis Eleftherios Pelechas Paraskevi V. Voulgari Alexandros A. Drosos 《Seminars in arthritis and rheumatism》2019,48(4):597-602
Objectives
To estimate the size of unmet needs in the treatment of early Rheumatoid Arthritis (eRA), using all the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs) in a long-term observational study.Materials and methods
538 patients with eRA were evaluated. The 2010 ACR/EULAR classification criteria were used. All patients were csDMARDs and bDMARDs-naive with disease duration less than one year. They were treated according to EULAR and ACR recommendations for RA. All the csDMARDs and bDMARDs were used. Clinical, laboratory findings with the disease activity score-28 and treatment decisions were all recorded as well as adverse drug reactions, reason of therapy termination, disease complications and comorbidities.Results
Methotrexate (58%) and Infliximab (37%) where the first csDMARD and bDMARD choice respectively. During follow-up, 14 patients were lost and 7 developed comorbidities. The final results are referred to 517 patients. Among those, 66% were treated with csDMARDs as monotherapy or in combination therapy with sustained low disease activity (LDA). However, 3.2% from this group neither achieved LDA, nor received bDMARDs, due to comorbidities. On the other hand, 34% were treated with bDMARDs with or without csDMARDs. The majority of them demonstrated sustained LDA. From this group, 17.7% never achieved LDA, despite that they switched and received all bDMARDs. Thus, 20.9% of our patients never achieved LDA.Conclusions
Using the current recommendations for RA therapy we successfully treated the majority of our patients. However, we found that the size of gap and the unmet needs for treatment is about 20%. 相似文献44.
Giatromanolaki A Sivridis E Simopoulos C Polychronidis A Gatter KC Harris AL Koukourakis MI 《Clinical & experimental metastasis》2002,19(8):673-679
Recent reports provide evidence that some growth factors behave as inhibitors of the apoptosis of the endothelial cells, bringing
forward the concept of vascular survival as a post-angiogenesis process. At least two different vasculature development processes
occur within a tumor: the angiogenic (formation of new vessels) and the vascular survival pathway, which is devoted to the
preservation of the newly-formed vessels in layers that lose contact with the adjacent normal tissue. We developed a method
to assess these processes in tissue samples. We noted that differences among tumors may exist not only in the tumor angiogenic
activity (TAA) but also in the vascular survival ability (VSA). One third of the highly angiogenic breast cancer cases examined
had a poor ability to maintain high vessel density in inner tumor areas. Both parameters are independently related to prognosis,
while VSA was directly related to tumor dimensions and node involvement. Patients with high TAA and VSA had a particularly
poor prognosis. It is suggested that although cancer angiogenic activity is important for the local invasion and dissemination
into vessels and lymphatics, the VSA may be important for the effective formation of viable tumor foci in lymph nodes or distant
organs. Recognition and quantification of the vascular survival ability in human tumors may significantly improve the prognostic
value of the assessment of tumor vasculature, and may help to stratify patients for clinical trials with novel anti-angiogenic
or angiotoxic drugs. Elucidation of the pathways may provide additional targets for antiangiogenic therapy.
This revised version was published online in July 2006 with corrections to the Cover Date. 相似文献
45.
Hrabina M Purohit A Oster JP Papanikolaou I Jain K Pascal P Sicard H Gouyon B Moingeon P Pauli G André C 《International archives of allergy and immunology》2007,142(1):11-18
BACKGROUND: Ash tree (Fraxinus excelsior) is the main representative of the Oleaceae family in temperate zones. Diagnosis of ash pollen allergy is made difficult due to (1) an overlapping pollinization period with Betulaceae, (2) non-inclusion in current diagnostic assays, and (3) some cross- reactivity with minor allergens from Betulaceae. The aim of this study was to calibrate an ash pollen in-house reference preparation (IHRP) in allergic patients in order to produce standardized products for diagnosis and immunotherapy purposes. METHODS: Ash pollen IHRP was extracted, ultrafiltered and freeze dried. Allergens in the extract were detected after 2-dimensional PAGE using specific sera and a monoclonal antibody. The Fra e 1 content of IHRP was evaluated by quantitative immunoprint. Forty-eight subjects from the North-East of France exhibiting clinical symptoms, a positive skin test and specific IgE levels > or =class 2 to ash pollen were recruited. IgE immunoprints were performed to select patients sensitized to the ash Fra e 1 allergen as opposed to cross-reacting allergens. Serial 10-fold dilutions of the IHRP were tested by skin prick tests in order to determine the concentration inducing a geometrical mean wheal diameter of 7 mm, said to correspond to an index of reactivity (IR) of 100 per millilitre. RESULTS: IgE-reactive molecules in IHRP comprise Fra e 1, Fra e 2, a 9-kDa molecule (presumably Fra e 3), as well as a doublet at 15 kDa and high molecular weight allergens. The 100 IR concentration of IHRP inducing a geometrical mean wheal diameter of 7 mm in 22 patients sensitized to Fra e 1 corresponds to the 1/126 (w/v) extraction ratio (i.e. 259 microg/ml of protein by Bradford) and contains 17 microg/ml of Fra e 1. The variability in total activity of 5 batches of standardized extracts was found to be significantly reduced when compared with 7 non-standardized extracts. CONCLUSION: An ash pollen IHRP was defined and molecularly characterized. Its successful standardization at 100 IR/ml in patients specifically sensitized to Fra e 1 allowed a skin reactivity-based calibration in properly diagnosed patients. Such a standardized ash pollen extract is a reliable tool to support immunotherapy of ash pollen allergy. 相似文献
46.
Donoso P Verpoest W Papanikolaou EG Liebaers I Fatemi HM Sermon K Staessen C Van der Elst J Devroey P 《Human reproduction (Oxford, England)》2007,22(4):1021-1025
BACKGROUND: The Belgian legislation imposes single embryo transfer (SET) on women of <36 years in their first treatment cycle to avoid multiple pregnancies. The aim of this study is to assess the impact of this legislation on the outcome of preimplantation genetic diagnosis (PGD) for inherited diseases in young women undergoing SET. METHODS: A retrospective analysis of PGD cycles for monogenic disorders and translocations in women <36 years on their first treatment cycle. Two groups of patients were defined according to the implementation of the Belgian legislation: (i) double embryo transfer (DET), January 2001-June 2003 (ii) SET, July 2003-June 2005. The primary and secondary outcome measures were delivery per embryo transfer and multiple pregnancy rates, respectively. A subgroup analysis for monogenic disorders and translocations was performed. RESULTS: 62 cycles were included in the DET group and 73 cycles in the SET group. The mean age, number of cumulus-oocyte complexes, number of fertilized oocytes, number of biopsied and cryopreserved embryos were comparable between both groups. There was no significant difference in the delivery rates between the DET and the SET groups (33.9% versus 27.4%, respectively). Multiple pregnancies were avoided when SET was performed. When monogenic disorders and chromosomal translocations were separately evaluated, no significant difference in the delivery rate after SET was observed. CONCLUSIONS: The implementation of a SET policy in young women undergoing PGD for monogenic disorders and translocations enables a significant reduction of multiple pregnancies without significantly affecting the delivery rate. 相似文献
47.
48.
Papanikolaou EG D'haeseleer E Verheyen G Van de Velde H Camus M Van Steirteghem A Devroey P Tournaye H 《Human reproduction (Oxford, England)》2005,20(11):3198-3203
INTRODUCTION: In a randomized controlled trial, we assessed whether pregnancy outcome would be improved by extending embryo culture to day 5 and transferring a blastocyst in patients with at least four good-quality embryos on day 3. METHODS: Multifollicular ovarian stimulation was performed with a GnRH agonist in 44% of patients and with a GnRH antagonist in 56%. Overall, 164 patients younger than 37 years fulfilled embryo quality criteria (at least four having at least six cells on the morning of day 3, maximum 20% anucleate fragments) on the third day of culture and were randomized to the day 3 (n = 84) or day 5 (n = 80) groups. Equal numbers of embryos (n = 2) were transferred in each group. RESULTS: Demographics, stimulation parameters and embryological data were comparable in the two groups. Blastocyst-stage transfer resulted in a significantly higher ongoing pregnancy rate [51.3 versus 27.4%; odds ratio (OR) 2.78, 95% confidence interval (CI) 1.45-5.34] and live birth rate (47.5 versus 27.4%; OR 2.40, 95% CI 1.25-4.59) compared with day-3 embryo transfer. A high twin birth rate was observed in both groups (36.8 versus 30.4%; P > 0.05). CONCLUSIONS: A threshold of four good embryos on the third day of embryo culture appears to indicate that the patient will benefit from embryo transfer at the blastocyst stage and have a better chance of achieving a live delivery than with cleavage-stage embryo transfer. 相似文献
49.
Maria E. Marketou MD PhD Fragiskos I. Parthenakis MD PhD Athanasia Kalyva PhD Charalampos Pontikoglou MD PhD Spyros Maragkoudakis MD PhD Joanna E. Kontaraki PhD Evangelos A. Zacharis MD PhD Gregory Chlouverakis PhD Alexandros Patrianakos MD PhD Helen A. Papadaki MD PhD Panos E. Vardas MD PhD 《Journal of clinical hypertension (Greenwich, Conn.)》2014,16(12):883-888
Stem cells have great clinical significance in many cardiovascular diseases. However, there are limited data regarding the involvement of mesenchymal stem cells (MSCs) in the pathophysiology of arterial hypertension. The aim of this study was to investigate the circulation of MSCs in patients with essential hypertension. The authors included 24 patients with untreated essential hypertension and 19 healthy individuals. Using flow cytometry, MSCs in peripheral blood, as a population of CD45−/CD34−/CD90+ cells and also as a population of CD45−/CD34−/CD105+ cells, were measured. The resulting counts were translated into the percentage of MSCs in the total cells. Hypertensive patients were shown to have increased circulating CD45−/CD34−/CD90+ compared with controls (0.0069%±0.012% compared with 0.00085%±0.0015%, respectively; P=.039). No significant difference in circulating CD45−/CD34−/CD105+ cells was found between hypertensive patients'' and normotensive patients'' peripheral blood (0.018%±0.013% compared with 0.015%±0.014%, respectively; P=.53). Notably, CD45−/CD34−/CD90+ circulating cells were positively correlated with left ventricular mass index (LVMI) (r=0.516, P<.001). Patients with essential hypertension have increased circulating MSCs compared with normotensive patients, and the number of MSCs is correlated with LVMI. These findings contribute to the understanding of the pathophysiology of hypertension and might suggest a future therapeutic target.In recent years there has been growing interest in the role of adult stem cells in the pathophysiology of cardiovascular diseases. Although it used to be believed that mammalian cardiomyocytes cease replication soon after birth and that the subsequent growth of the heart was attributable only to cardiomyocyte hypertrophy, newer studies have demonstrated a small degree of cardiogenesis and cardiomyocyte turnover that occurs throughout life.1, 2 These findings led to further research into the contribution of stem cells to the pathophysiology of cardiovascular disorders that has raised the hope of developing new therapeutic approaches. Stem cells have the potential for self‐renewal and differentiation and are the origin cells of various mature cells.Mesenchymal stem cells (MSCs) are also known to have a highly plastic differentiation potential that includes not only adipogenesis, osteogenesis, and chondrogenesis, but also endothelial, cardiovascular,3 and neovascular differentiation.4, 5, 6 Although present in only very small numbers in peripheral blood, in recent years stem and progenitor cells have been implicated in ventricular remodeling and are thought to be of great clinical significance in the pathophysiology of heart failure and atheromatosis. Previous studies have indicated that MSCs derived from peripheral blood, apart from their multilineage potential, can also be used for cellular and gene therapies.7 Human MSCs isolated from adult bone marrow provide a model for the development of stem cell therapeutics and could find application in the cardiovascular system—although this is still under investigation.8 Under normal conditions, endogenous cardiac progenitor cells are responsible for homeostasis in the heart.9 However, it appears that under conditions of stress, this may change, with stem cells from extra‐cardiac sources also playing a role. An interesting experimental study has shown that an increase in preload results in the mobilization of progenitor cells from the bone marrow for use in neovascularization, which plays an important role in cardiac hypertrophy.10 There are indications that the recruitment of bone marrow–derived cells is involved in cardiac myocyte hypertrophy and maintenance of function in response to pressure overload.11 A recent study from our department has shown increased expression of myocardin and GATA4 genes in the peripheral blood mononuclear cell fraction of hypertensive patients, implying the presence of mesenchymal progenitor cells in the peripheral blood that could possibly be intended to differentiate into cells of the cardiac series.12 Interestingly, in the patients in that study, myocardin and GATA4 expression was associated with both blood pressure (BP) levels and left ventricular hypertrophy (LVH).To date, most published reports concerning the cardiovascular applications of stem cells have focused on their role in myocardial infarction and in heart failure. Very little work has been done on arterial hypertension, and most has concerned endothelial progenitor cells. The role and behavior of MSCs in patients with essential hypertension is unknown. In a recent animal study, it was shown that the degree to which angiotensin II increased neointima formation was statistically correlated with the increased incorporation of fluorescent bone marrow–derived smooth muscle cells, and that this was inhibited by angiotensin‐1 receptor antagonism.13 Based on the hypothesis that MSCs participate in pathophysiological processes that contribute to hypertension, and on the assumption that the behavior of MSCs is altered in hypertensive patients, we carried out the first flow cytometric analysis of CD45−/CD34−/CD90+ and CD45−/CD34−/CD105+ in the peripheral blood of those patients compared with healthy individuals. 相似文献
50.
Mohammad A. Zafar Julia Fayanne Chen Jinlin Wu Yupeng Li Dimitra Papanikolaou Mohamed Abdelbaky Thais Faggion Vinholo John A. Rizzo Bulat A. Ziganshin Sandip K. Mukherjee John A. Elefteriades 《The Journal of thoracic and cardiovascular surgery》2021,161(2):498-511.e1
ObjectivesElucidating critical aortic diameters at which natural complications (rupture, dissection, and death) occur is of paramount importance to guide timely surgical intervention. Natural history knowledge for descending thoracic and thoracoabdominal aortic aneurysms is sparse. Our small early studies recommended repairing descending thoracic and thoracoabdominal aortic aneurysms before a critical diameter of 7.0 cm. We focus exclusively on a large number of descending thoracic and thoracoabdominal aortic aneurysms followed over time, enabling a more detailed analysis with greater granularity across aortic sizes.MethodsAortic diameters and long-term complications of 907 patients with descending thoracic and thoracoabdominal aortic aneurysms were reviewed. Growth rates (instrumental variables approach), yearly complication rates, 5-year event-free survival (Kaplan–Meier), and risk of complications as a function of aortic height index (aortic diameter [centimeters]/height [meters]) (competing-risks regression) were calculated.ResultsEstimated mean growth rate of descending thoracic and thoracoabdominal aortic aneurysms was 0.19 cm/year, increasing with increasing aortic size. Median size at acute type B dissection was 4.1 cm. Some 80% of dissections occurred below 5 cm, whereas 93% of ruptures occurred above 5 cm. Descending thoracic and thoracoabdominal aortic aneurysm diameter 6 cm or greater was associated with a 19% yearly rate of rupture, dissection, or death. Five-year complication-free survival progressively decreased with increasing aortic height index. Hazard of complications showed a 6-fold increase at an aortic height index of 4.2 or greater compared with an aortic height index of 3.0 to 3.5 (P < .05). The probability of fatal complications (aortic rupture or death) increased sharply at 2 hinge points: 6.0 and 6.5 cm.ConclusionsAcute type B dissections occur frequently at small aortic sizes; thus, prophylactic size-based surgery may not afford a means for dissection protection. However, fatal complications increase dramatically at 6.0 cm, suggesting that preemptive intervention before that criterion can save lives. 相似文献